GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Altman Z2-Score

Nanomix (Nanomix) Altman Z2-Score : -479.63 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Nanomix has a Altman Z2-Score of -479.63, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Nanomix's Altman Z2-Score or its related term are showing as below:


Nanomix Altman Z2-Score Historical Data

The historical data trend for Nanomix's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Altman Z2-Score Chart

Nanomix Annual Data
Trend Dec20 Dec21 Dec22
Altman Z2-Score
- -459.68 -479.63

Nanomix Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -459.68 -379.18 -444.11 -451.06 -479.63

Competitive Comparison of Nanomix's Altman Z2-Score

For the Medical Devices subindustry, Nanomix's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanomix's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Nanomix's Altman Z2-Score falls into.



Nanomix Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Nanomix's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-4.0428+3.26*-121.5071+6.72*-8.335+1.05*-0.9337
=-479.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2022:
Total Assets was $0.98 Mil.
Total Current Assets was $0.08 Mil.
Total Current Liabilities was $4.05 Mil.
Retained Earnings was $-119.32 Mil.
Pre-Tax Income was -3.02 + -3.812 + -2.616 + -2.845 = $-12.29 Mil.
Interest Expense was -1.159 + -1.083 + -1.019 + -0.847 = $-4.11 Mil.
Total Liabilities was $14.82 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.08 - 4.05)/0.982
=-4.0428

X2=Retained Earnings/Total Assets
=-119.32/0.982
=-121.5071

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-12.293 - -4.108)/0.982
=-8.335

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-13.833 - 0)/14.815
=-0.9337

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Nanomix has a Altman Z2-Score of -479.63 indicating it is in Distress Zones.


Nanomix  (OTCPK:NNMX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Nanomix Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Nanomix's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanomix (Nanomix) Business Description

Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338